TLC News and Press, Taiwan Liposome Company Ltd. From 05/24/21

InspirMed, a subsidiary of Taiwan Liposome (TLC) presents findings from two separate studies in rats on ISPM21 and ISPM19, respectively, as well as from a ISPM19 lung deposition study at the 23rd International Society for Aerosols in Medicine ((ISAM)) Congress.Pharmacokinetic studie...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of proprietary inhalable liposome formulation programs, recently presented data on the potential advantages o...

Gainers: Annovis Bio ANVS +112%, Gracell Biotechnologies (GRCL) +24%, Metacrine MTCR +16%, Sensei Biotherapeutics (SNSE) +14%, Longeveron (LGVN) +12%.Losers: Precipio (PRPO) -12%, Cullinan Oncology CGEM -8%, Navidea Biopharmaceutical...

Taiwan Liposome (TLC): Q1 GAAP EPS of -$0.10 beats by $0.07.Revenue of $0.4M (flat Y/Y) misses by $0.08M.Shares +14% PM.Press Release For further details see: Taiwan Liposome EPS beats by $0.07, misses on revenue

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 03, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it once again ranks in the Top 5% i...

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC, TWO: 4152) that specializes in the development of inhalable liposome formulation programs, announced today that a late-breaking abstract describing the po...

The following slide deck was published by Taiwan Liposome Company, Ltd. in conjunction with this event. For further details see: Taiwan Liposome presents at Oppenheimer 31st Annual Healthcare Conference - slideshow

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Company’s management t...

Taiwan Liposome (TLC): FY GAAP EPS of -$0.44.Revenue of $3.63M (-48.1% Y/Y)Press Release For further details see: Taiwan Liposome reports FY results